Jaguar Animal Health Inc logo

JAGXJaguar Animal Health Inc

NASDAQ · Healthcare · Biotechnology

$0.74

+$0.01 (+1.71%)

Jaguar Animal Health Inc (JAGX) is a biotechnology company listed on NASDAQ. It is led by Lisa A. Conte, based in 200 Pine Street, San Francisco, CA, United States, 94104, with about 47 employees. Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Latest reported JAGX revenue for 2026-06-30 was $1.2M. Net income was -$12.8M. Revenue was down 94.0% from 2026-03-31 to 2026-06-30. JAGX currently screens at market cap $1.7M.

Use this JAGX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the JAGX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the JAGX SEC filings page. Lician reads the product cache first so this HTML stays unique to Jaguar Animal Health Inc even when a live quote feed is slow.

About Jaguar Animal Health Inc

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

JAGX Key Statistics

Market Cap

$1.67M

Volume

56,366

Previous Close

$0.91

Day Range

$0.87$0.97

0

P/B Ratio

1.62

EPS

-$22.97

Revenue

$11.51M

Net Income

-$53.58M

Gross Profit

$7.74M

Free Cash Flow

$0.00

Revenue Growth

-1.5%

Profit Margin

-465.4%

Debt to Equity

0.00

Employees

47

JAGX Financials

Annual income statement in USD. Latest reported periods first.

JAGX annual income statement across FY2025, FY2024
LineFY2025FY2024
Revenue$11.51M$11.69M
Cost of Revenue$3.77M$1.96M
Gross Profit$7.74M$9.73M
Operating Income-$45.91M-$30.83M
Net Income-$53.58M-$38.49M
EPS (Diluted)-$22.97-$130.69

Total Assets

$38.32M

Total Debt

$0.00

Shareholders' Equity

-$18.69M

Cash & Equivalents

$968.00K

Operating Cash Flow

-$23.69M

Free Cash Flow

$0.00

Jaguar Animal Health Inc Company Information

Founder, CEO, President & Director
Lisa A. Conte
Headquarters
200 Pine Street, San Francisco, CA, United States, 94104
Phone
415 371 8300
IPO / Founded
2015-05-13
Industry
Biotechnology
Data Updated:

Upcoming Events for JAGX